The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.


  • Kalypsys Initiates Second Phase I Clinical Trial of Topical iNOS Inhibitor
  • Kalypsys Raises $100 Million in a Series C Financing
  • Kalypsys on Track to Complete Phase Ia Study for Drug Candidate, KD3010, for Metabolic Disorders by End of October
  • Kalypsys Appoints 2 Executives to Leadership Team
  • Panasonic and Kalypsys Collaborate For Development of Drug Discovery Systems
  • Kalypsys Announces Small Molecule Research Collaboration With Alcon
  • More >


    There are no events scheduled at this time.